4.7 Article

Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors

期刊

CLINICAL CANCER RESEARCH
卷 28, 期 1, 页码 95-105

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-21-1181

关键词

-

类别

资金

  1. Bristol Myers Squibb (Princeton, NJ)
  2. ONO Pharmaceutical Company Ltd. (Osaka, Japan)
  3. Bristol Myers Squibb

向作者/读者索取更多资源

BMS-986148, a mesothelin-directed antibody-drug conjugate, showed acceptable safety and tolerability in patients and demonstrated preliminary clinical activity. This suggests that combining directed cytotoxic therapies with checkpoint inhibitors may be a potential multimodal therapeutic strategy in advanced solid tumors.
Purpose: To assess the safety and tolerability of BMS-986148, a mesothelin-directed antibody-drug conjugate (ADC) +/- nivolumab, in patients with selected tumors. Patients and Methods: In an international phase I/IIa study [NCE02341625 (CA008-002)], patients received BMS-986 148 monotherapy (0.1-1.6 mg/kg intravenously (i.v.) every 3 weeks or 0.4 or 0.6 mg/kg i.v. once weekly; n = 96) or BMS-986148 0.8 mg/kg nivolumab 360 mg i.v. every 3 weeks (n = 30). The primary endpoint was safety and tolerability. Results: In CA008-002, the most common 10%) treatmentrelated adverse events (TRAEs) included increased aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase. Grade 3/4 TRAEs occurred in 42 patients (49%) receiving BMS-986148 every 3 weeks monotherapy, three (25%) receiving BMS-986148 once-weekly monotherapy, and 10 (33%) receiving BMS-986148 nivolumab every 3 weeks. Overall, 17 of 126 patients (13%) discontinued because of a TRAE. The MTD of BMS-986148 was 1.2 mg/kg i.v. every 3 weeks. The safety profile of BMS-986148 +/- nivolumab was similar to that of BMS-986148 monotherapy (0.8 mg/kg). Active ADC exposures increased in a dose-proportional manner with both dosing regimens (every 3 weeks and once weekly). Preliminary clinical activity was observ ed with BMS-986148 nivolumab. No association between mesothelin expression and response was detected. Conclusions: BMS-986148 +/- nivolumab demonstrated a clinically manageable safety profile and preliminary evidence of clinical activity, supporting additional studies combining directed cytotoxic therapies with checkpoint inhibitors as potential multimodal therapeutic strategies in patients with advanced solid tumors.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据